Date Announced: 18 Mar 2020
André Guedes, DROPLITE CEO.
ICFO start-up DROPLITE will receive support and mentoring from the InsudPharma network to compete in new rounds of funding.
Barcelona, Spain -- DROPLITE, a company spun out of ICFO in December 2018 after developing for more than four years in ICFO’s KTT Launchpad, is one of three start-ups to win the third edition of the ChemoStart initiative. This accelerator program, promoted by Insud Pharma, provides support for startups and companies that design innovative projects in the field of health and medical care.
DROPLITE, which markets a biosensing device using lab-on-a-chip technology developed in ICFO to test and monitor health conditions in humans and animals, along with companies Varixio and Neosonics, were three of twelve finalists to pitch their projects in January before an external jury made up of leaders in the health sector.
As winners, they will each receive Insud Pharm’s assistance in advancing their health solutions based on their specific needs in areas such as internationalization, marketing, scalability or business plan development.
Over the course of the coming months, Insud Pharma will support these three ventures, providing resources and access to mentors who will advise them as they prepare for Investor Day, where they will present to InsudPharma’s network of investors to obtain the necessary financing to continue promoting projects in the future.
Web Site: www.droplite.com